MX2018014024A - Terapias de combinación con moduladores del receptor x farnesoide (fxr). - Google Patents

Terapias de combinación con moduladores del receptor x farnesoide (fxr).

Info

Publication number
MX2018014024A
MX2018014024A MX2018014024A MX2018014024A MX2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A MX 2018014024 A MX2018014024 A MX 2018014024A
Authority
MX
Mexico
Prior art keywords
inhibitor
fxr
farnesoid
modulators
receptor
Prior art date
Application number
MX2018014024A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Pratt Benjamin
Mohan Raju
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of MX2018014024A publication Critical patent/MX2018014024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018014024A 2016-05-25 2017-05-25 Terapias de combinación con moduladores del receptor x farnesoide (fxr). MX2018014024A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (1)

Publication Number Publication Date
MX2018014024A true MX2018014024A (es) 2019-08-29

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014024A MX2018014024A (es) 2016-05-25 2017-05-25 Terapias de combinación con moduladores del receptor x farnesoide (fxr).

Country Status (13)

Country Link
US (1) US20200397798A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463373A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019517478A (cg-RX-API-DMAC10.html)
KR (1) KR20190040936A (cg-RX-API-DMAC10.html)
CN (1) CN109843298A (cg-RX-API-DMAC10.html)
AU (1) AU2017270221A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073460A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025007A1 (cg-RX-API-DMAC10.html)
IL (1) IL263179A (cg-RX-API-DMAC10.html)
MX (1) MX2018014024A (cg-RX-API-DMAC10.html)
RU (1) RU2018145776A (cg-RX-API-DMAC10.html)
SG (2) SG11201810290WA (cg-RX-API-DMAC10.html)
WO (1) WO2017205684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
BR112018073460A2 (pt) 2019-07-09
AU2017270221A1 (en) 2018-12-20
EP3463373A4 (en) 2020-04-22
WO2017205684A1 (en) 2017-11-30
CN109843298A (zh) 2019-06-04
SG10202011660RA (en) 2020-12-30
JP2019517478A (ja) 2019-06-24
KR20190040936A (ko) 2019-04-19
EP3463373A1 (en) 2019-04-10
RU2018145776A3 (cg-RX-API-DMAC10.html) 2021-03-01
CA3025007A1 (en) 2017-11-30
RU2018145776A (ru) 2020-06-26
US20200397798A1 (en) 2020-12-24
IL263179A (en) 2018-12-31
SG11201810290WA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
BR112018073460A2 (pt) terapias combinadas usando moduladores do receptor farnesoide x (fxr)
PH12019501010A1 (en) Arginase inhibitor combination therapies
EP4424364A3 (en) Methods of treating liver disease
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2025002686A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo
MX2020006115A (es) Inhibidores de la vía de respuesta al estrés integrada.
MX2019003364A (es) Composiciones oftalmicas que comprenden ciclosporina.
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
CL2017002686A1 (es) Métodos para tratar o prevenir dolor de cabeza por migraña
ES2692773T3 (es) Tratamientos para la fibrosis
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
WO2018231905A8 (en) Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
MX2015015221A (es) Nanoportadores sintéticos tolerogénicos y macromoléculas terapéuticas para efectos farmacodinámicos reducidos o intensificados.
EP4545143A3 (en) Early intervention methods to prevent or ameliorate toxicity
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX383893B (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
MX2018010862A (es) Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas.
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
MX2016010011A (es) Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.
MX2022014634A (es) Metodos para la administracion linfatica de agentes activos.
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2020013269A (es) Inhibidores de la vía de respuesta al estrés integrada.